



## NEOSTIM DL

**NEOSTIM DL IS A DUAL LAYER AMNION DERIVED ALLOGRAFT OPTIMIZED FOR WOUND COVERING, PROTECTION, AND ADVANCED WOUND TREATMENT.**

### THE NEOSTIM DL ADVANTAGE

Provides a reliable protective wound covering • 5-year shelf life at ambient temperature storage  
Adheres easily to wounds including those with irregular surfaces • Immune privileged  
Dehydrated extracellular matrix acts as a scaffold supporting the native tissue

### ORDERING INFORMATION (Q4267)

Product #	Size	Total Units (Per Sqcm)
NSD-020101	1x1	1
NSD-020102	1x2	2
NSD-020202	2x2	4
NSD-020203	2x3	6
NSD-020404	4x4	16
NSD-020406	4x6	24
NSD-020408	4x8	32
NSD-021016	10x16	160
NSD-021018	10x18	180

**NeoStim DL** is an amniotic membrane allograft derived from a prescreened mother with a planned C-section delivery. **NeoStim DL** is manufactured in compliance with FDA regulations and AATB guidance. The membrane is minimally processed to preserve the native structure of the tissue, dehydrated, and terminally sterilized. **NeoStim DL is confirmed by the FDA Tissue Reference Group to meet the criteria for regulation solely under Section 361 of the PHS Act as defined in 21 CFR Part 1271.**



**VISIT OUR WEBSITE**

orders@accessobio.com • www.accessobio.com • 775.762.8068



# NEOSTIM DL

## Why Amniotic Membrane?

Human amniotic membrane forms the innermost layer of placenta tissue. The avascular membrane acts as a protective barrier for the developing fetus. Its properties provide a wide variety of potential benefits.

### Protective Covering

The membrane sheet provides a protective covering that may aid in wound management

### Immunogenicity

The amniotic membrane has unique non-immunological properties

### Scaffold

The extracellular matrix acts as a scaffolding and may potentiate the migration and adhesion of resident cells<sup>2</sup>


### Growth Factors

The membrane is a natural source of cytokines and growth factors<sup>3</sup>

## Why NeoStim?

NeoStim has been shown to be effective as a protective covering in the management of chronic non-healing foot ulcers including diabetic, pressure, and venous ulcers.

In a 10 patient case series, 95% of wound closure was achieved after 8 weeks of treatment in patients who previously failed standard of care.



## NeoStim Allografts

The NeoStim family of allografts are dehydrated, terminally irradiated membranes. The allograft family is available in multiple configurations and sizes to accommodate a variety of physician preferences.

NeoStim is regulated under Section 361 of the Public Health Service Act and is intended for homologous use.

## Acesso Quality

The NeoStim family of allografts are processed in compliance with all current Good Tissue Practices as mandated by the United States Food and Drug Administration and the American Association of Tissue Banks. We pride ourselves on quality standards and testing that meet or exceed industry standards.

## Our Process

